ArticleJAMA network open2025
Prevalence of BRCA1 and BRCA2 Variants in an Unselected Population of Women With Breast Cancer.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring the hereditary genetic mutational landscape of breast and ovarian cancer in Estonia.Scientific reports · 2026Article
- The Complex Path from Mammary Ductal Hyperplasia to Breast Cancer: Elevated Malignancy Risk in Atypical Forms.Biomedicines · 2026Review
- Clinical Characteristics and Long-Term Outcomes of Young Women With Breast Cancer: A Multicenter Study From Uruguay.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Importance: Barriers to germline testing make it difficult to determine the prevalence of pathogenic or likely pathogenic (P/LP) variants in BRCA1 and BRCA2 in underrepresented populations. Objective: To determine P/LP variants in BRCA1 and BRCA2 in women with breast cancer enrolled in the Implementing Next-Generation Sequencing for Precision Intervention and Risk Evaluation (INSPIRE) study. Design, Setting, and Participants: This cohort study included patients from City of Hope Duarte, California, and Upland, California, with a breast cancer diagnosis of any stage (0 to IV) from July 2020 to October 2023 who were enrolled in the INSPIRE biorepository study. Blood, buccal smears, or saliva were collected for germline testing of 155 genes. Data were analyzed from October 2023 to December 2024. Exposures: Women with breast cancer, including underrepresented populations, received germline testing to determine P/LP variants in BRCA1 and BRCA2 genes. Main Outcomes and Measures: The main outcome was prevalence of P/LP variants in BRCA1 and BRCA2 in women with breast cancer. Results: A total of 2401 women with breast cancer underwent germline testing, including 136 African American or Black (5.7%), 365 Asian (15.2%), 15 American Indian or Alaska Native women (0.5%), 8 Native Hawaiian or Other Pacific Islander women (0.3%), and 1666 White (69.4%), 86 Other (3.6%), and 125 unknown (5.2%). Ethnicity was reported for 737 Hispanic or Latina women (30.7%) and 1545 non-Hispanic women (64.3%). P/LP variants in BRCA1 or BRCA2 were identified in 16 Asian women (4.4%), 11 African American or Black women (8.1%), and 80 White women (4.8%). Hispanic women with breast cancer were 2.58 times as likely as non-Hispanic women to carry a P/LP germline variant in BRCA1 than BRCA2 variants (odds ratio [OR], 2.58 [95% CI, 1.16-5.88]; P = .02). P/LP variants in BRCA1 were more likely to be identified in Hispanic women (22 of 737 [3.0%]) than in non-Hispanic women (25 of 1545 [1.6%]) (OR, 1.87; [95% CI, 1.04-3.34]; P = .02). Additionally, 16 of 116 women older than age 60 years (13.7%) were also found to have P/LP variants. Conclusions and Relevance: This large cohort study of women with breast cancer who underwent germline testing provided information about BRCA1 and BRCA2 in a population enriched for Hispanic women and reported the prevalence of P/LP variants when universal BRCA1 and BRCA2 testing is offered to women with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.